Comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril on diabetes-induced cardiovascular complications in type 1 diabetes in rats

International Journal of Diabetes and Metabolism

Volumn 19, Issue 1, 2011, Pages 11-18

  Goyal, Bhoomika R ^a   Bhadada, Shraddha V ^a   Patel, Mayur M ^a  

^a NIRMA UNIVERSITY   (India)

Author keywords

Anti hypertensives; Cardiovascular complications; Type 1 diabetes mellitus

Indexed keywords

ATENOLOL; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; PERINDOPRIL; RAMIPRIL; SPIRONOLACTONE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; BRADYCARDIA; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG RESPONSE; DYSLIPIDEMIA; FEMALE; HEART HEMODYNAMICS; HEART HYPERTROPHY; HEART INDEX; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NONHUMAN; RAT; STREPTOZOCIN DIABETES; WISTAR RAT;

EID: 80051605066     PISSN: 16067754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Fang ZY, Prins JB, Marwick TH. Diabetic Cardiomyopathy: Evidences, mechanism and therapeutic implications. Endocr Rev 2004; 25: 543-567.
2. Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002; 25: 134-147.
3. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905-912.
4. LeWinter MM. Diabetic cardiomyopathy: an overview. Coron Artery Dis 1996; 7: 95-98.
5. Savage MP, Krolewski AS, Kenien GG, Lebeis MP, Christlieb AR, Lewis SM. Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor. Am J Cardiol 1988; 62: 665-669.
6. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 71: 12A-16A.
7. Ramires F, Salemi V, Ianni B, Fernandes F, Martins D, Billate A, Neto E, Mady C. Aldosterone Antagonism in an Inflammatory State: Evidence for Myocardial Protection. J Renin Angiotensin Aldosterone Syst 2006; 7: 162-167.
8. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999; 341: 709-717.
9. Sawicki PT, Siebenhofer A. Betablockers and Diabetes Mellitus. J Clin Basic Cardiol 2001; 14: 17-20.
10. Bell DS. Advantages of a third generation beta blocker in patients with diabetes mellitus. Am J Cardiol 2004; 93: 49-52.
11. Libertti A, Catalano M. Lipid profile during antihypertensive treatment. The SLIP Study Group. Study on Lipids with Isoptin Press. Drugs 1993; 46: 16-23.
12. Bangaru RA, Gandhi TP, Goyal RK. Studies on the effects of enalapril treatment in diabetic hypertensive rats. Ind J Pharmacol 1992; 24: 62.
13. Shenoy AG. Goyal RK. Improvement of insulin sensitivity by perindopril in spontaneously hypertensive and streptozotocin-diabetic rats. Ind J Pharmacol 2002; 34: 156-164
14. Umrani DN, Goyal RK. Beneficial effects of fenoldopam treatment on renal functions in streptozotocin induced diabetic rats. Clin Exp Hypertens 2002; 24: 207-219.
15. Goyal RK. Hyperinsulinemia and insulin resistance in hypertension: Differential effects of antihypertensive agents. Clin Exp Hypertens 1999; 21: 167-179.
16. Rodrigues B, Goyal RK, Mc Neill JH. Effects of hydralazine on STZ-induced diabetes rats - prevention of hyperlipidemia and improvement in cardiac function. J Pharmcol Expt Ther 1986; 237: 299-307.
17. Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA. Insulin Resistance and Hyperinsulinemia Are Related to Plasma Aldosterone Levels in Hypertensive Patients. Diabetes Care 2007; 30: 2349-2354.
18. Corbould A. Effects of Spironolactone on Glucose Transport and lnterleukin-6 Secretion in Adipose Cells of Women. Horm Metab Res 2007; 39: 915-918.
19. Brichard S, Ketelslegers JM, Lambert AE. Renal function, glycaemic control and perindopril in diabetic patients. Arch Mal Coeur Vaiss. 1989; 82: 57-61.
20. Uchida K, Azukizawa S, Kigoshi T, Nakano S, Kaneko M, Morimoto S, Matsui A. Effects of perindopril on glucose and lipid metabolism in patients with mild-to-moderate essential hypertension and glucose intolerance. Clin Ther 1994; 16: 466-470.
21. Derosa G, Cicero AFG, Ciccarelli L, Fogari R. A randomized, doubleblind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. Clin Ther 2003; 25: 2006-2021.
22. Fogari R, Zoppi A, Lazzari P, Preti P, Mugellini A, Corradi L, Lusardi P. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol 1998; 32, 616-620.
23. Kaplan NM. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149: 1514-1520.
24. Egan BM, Stepniakowski K, Goodfriend TL. Renin and aldosterone are higher and the hyperinsulinemic effect of salt restriction greater in subjects with risk factors clustering. Am J Hypertens 1994; 7: 886-893.
25. Goodfriend TL, Ball DL, Elliott ME, Chabhi A, Duong T, Raff H, Schneider EG, Brown RD, Weinberger MH. Fatty acids may regulate aldosterone secretion and mediate some of insulin's effects on blood pressure. Prostaglandins Leukot Essent Fatty Acids 1993; 48: 43-50.
26. Weidmann P, Uehlinger DE, Gerber A. Antihypertensive treatment and serum lipoproteins. J Hypertens 1985; 3: 297-306.
27. Itskovitz HD. Alpha1 blockers: Safe effective treatment for hypertension. Postgraduate Med 1991; 89: 89-112.
28. Lithell H, Weiner L, Selinus I, Vessby B. Comparision of the effects of bisoprolol and atenolol on lipoprotein concentrations and blood pressure. J Cardiovasc Pharmacol 1986; 8: 128-133.
29. Kannel WB. Metabolic risk factors for coronary heart disease in women. Perspective from the Framingham study. Am Heart J. 1987; 114: 413-419.
30. Castelli WP. The triglyceride issue: A view from Framingham. Am Heart J 1986; 112:432-437.
31. Han S, Kim C, Kim H, Jee Y, Song H, Lee M, Han K, Kim H. Kang Y, Han J, Kim Y, Cha DR. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006; 17: 1362-1372.
32. Bunag, RD, Tomita T, Saski S. Streptozocin diabetic rats are hypertensive despite reduced hypothalamic responsiveness. Hypertension 1982; 4: 556-565.
33. Funakawa S, Okahara T, Imanishi M, Komori T, Yamamoto K, Tochino Y. Renin angiotensin system and prostacyclin biosynthesis in STZ diabetic rats. Eur J Pharmacol 1983; 94: 27-33.
34. Savarese JJ, Berkowitz BA. Beta adrenergic receptors decrease in diabetic rat hearts. Life Sci 1979; 25: 2075-2078.
35. Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994; 24: 571-575
36. Yee KM, Struthers AD. Aldosterone blunts baroreflex action in man. Clin Sci 1998; 95: 687-692
37. Hoffmann J, Grimm W, Menz V, Muller HH, Maisch B. Heart rate variability and baroreflex sensitivity in idiopathic dilated cardiomyopathy. Heart 2000; 83: 531-538.
38. Weber MA, Purdy RE. Catecholamine mediated constrictor effect of aldosterone on vascular smooth muscles. Life Sci 1982; 30: 2009-2017.
39. Zhang Y, Liu J, Wang Y, Zhang Q, Gong Y, Liu N. Intervention of spironolactone on heart rate variability and its circardian rhythm in patients with heart failure. J Chin Clin Med 2006; 1: 264-267.
40. Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram: prevalence, incidence and mortality in the Framingham study. Ann Int Med 1969; 71: 89-105.
41. Gorden T, Kannel WB. Premature mortality from coronary heart disease. The Framingham Study. JAMA 1971; 215: 1617-1625.
42. Grossman E, Shemesh J, Shamiss, A, Thaler M, Carroll J, Rosenthal T. Left Ventricular Mass in Diabetes. Arch Int Med 1992; 152: 1001-1004.
43. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995; 269: 657-662.
44. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest 1994; 93: 2578-2583.
45. Tsukashita M, Marui A, Nishina T, Yoshikawa E, Kanemitsu H, Wang J, Ikeda T, Komeda M. Spironolactone alleviates late cardiac remodeling after left ventricular restoration surgery. J Thorac Cardiovasc Surg 2008; 136: 58-64.
46. Nguyen T, El Salibi E, Rouleau JL. Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat: effects of ramipril and hydralazine. Circulation 1998; 98: 2074-2080.
47. Nielsen FS, Sato A, Ali S, Tarnow L, Smidt UM, Kastrup J, Parving HH. Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients. Diabetes Care 1998; 21: 804-809.
48. Cooper ME, Cao Z, Rumble JR, Jandeleit K, Allen TJ, Gilbert RE. Attenuation of diabetes-associated mesenteric vascular hypertrophy with perindopril: morphological and molecular biological studies. Metabolism 1998; 47: 24-27.
49. Goyal BR, Mesariya P, Goyal RK., Mehta A. A. Effect of telmisartan on cardiovascular complications associated with STZ-diabetic rats. Mol Cell Biochem 2008; 314: 123-131
50. Goyal BR, Solanki N, Goyal RK, Mehta AA. Investigation into the cardiac effects of spironolactone in the experimental model of type 1 diabetes. J Cardiovas Pharmacol 2009; 54: 502-509
51. Goyal BR, Parmar K, Goyal RK, Mehta AA. Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type-2 diabetic rats. Pharmacol Rep 2011 63(4) (In-press)